South Korean AI-based digital healthcare company AIDOT (CEO Jaehun Jung) announced on November 3 that it has signed a supply agreement in Chile for its AI-powered cervical cancer early screening solution, Cerviray AI.

The agreement is based on a minimum order quantity (MOQ) of $2 million (approximately 2.8 billion KRW) over at least three years. Following its entry into the Bolivian and Mexican markets, AIDOT is further expanding its presence across Latin America.

AIDOT has previously collaborated with local healthcare professionals in Bolivia and Mexico on public health programs and clinical projects using Cerviray AI. This new Chilean contract builds on those achievements and is expected to facilitate further expansion into neighboring countries such as Peru and Colombia.

Cerviray AI is delivered as an on-device solution, allowing it to function effectively even in regions with limited internet connectivity or IT infrastructure. This enables early screening services to reach rural and remote areas with underdeveloped healthcare infrastructure, contributing to improved national cancer detection rates and reducing healthcare disparities.

In September, a free cervical cancer screening program will launch in Chile, led by local obstetricians Dr. Fernando Heredia Muñoz and Dr. Juan Landeros Sanzana. Commercial operations will begin immediately, ensuring that Cerviray AI is quickly integrated into Chile’s healthcare system.

The system combines portable hardware cameras with AI interpretation software, enabling fast and efficient cervical cancer screening even in low- and middle-income countries (LMICs). Cerviray AI is currently being expanded globally through public health initiatives, official development assistance (ODA) programs, and clinical research projects.

BioTimes / Reporter Jisoo Kim